ストックスクリーナーアプリを入手
12.16
3.75%
0.44
アフターアワーズ：
12.17
0.010
+0.08%
Candel Therapeutics Inc (CADL) 最新ニュース
Candel Therapeutics (NASDAQ: CADL) insider plans 7,000-share 10b5-1 sale - Stock Titan
Candel Therapeutics (NASDAQ:CADL) Trading 6.4% Higher Following Analyst Upgrade - MarketBeat
Freedom Broker raises Candel Therapeutics stock price target on trial progress - Investing.com Canada
Weekly Recap: CAN-2409 BLA filing, 2027 U.S. launch target and Q2 widened loss, shares up - TradingView
Research Analysts Set Expectations for CADL Q3 Earnings - MarketBeat
CADL Q3 EPS Estimate Reduced by Brookline Capital Markets - MarketBeat
(CADL) Risk Channels and Responsive Allocation - Stock Traders Daily
Candel Therapeutics (NASDAQ:CADL) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow - Stocktwits
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally? - Stocktwits
Candel Therapeutics (NASDAQ:CADL) Stock Price Expected to Rise, Bank of America Analyst Says - MarketBeat
LifeSci Capital Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Candel Therapeutics (NASDAQ:CADL) Stock Price Down 4.6% After Earnings Miss - MarketBeat
Candel Therapeutics, Inc. Stock 12‑Month Price Target Raised to $20.88, Implies 77% Upside - TradingView
BofA Adjusts Price Target on Candel Therapeutics to $12 From $9 - Moomoo
Equities Analysts Offer Predictions for CADL FY2028 Earnings - MarketBeat
Biotech Stocks At 52-Week HighsPARK +10%, AVAH +24%, CADL +10% On Q2 Reports, LH, COAG - RTTNews
A Quick Look at Today's Ratings for Candel Therapeutics(CADL.US), With a Forecast Between $12 to $23 - Moomoo
Candel Therapeutics (NASDAQ:CADL) Releases Earnings Results, Misses Expectations By $0.30 EPS - MarketBeat
CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4 - TradingView
Candel Therapeutics (NASDAQ:CADL) Sets New 12-Month HighHere's What Happened - MarketBeat
HC Wainwright Reaffirms Buy Rating for Candel Therapeutics (NASDAQ:CADL) - MarketBeat
Candel Therapeutics Q2 EPS of $(0.52) misses estimates - scanx.trade
Candel Therapeutics Reports Q2 2026 Financials and Pipeline Progress in SEC Form 10-Q - Kalkine Media
Candel Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
This Small-Cap Biotech Is Having Its Best Week In A Month – Here’s What’s Driving It - Stocktwits
Form 8K Candel Therapeutics Inc For: 13 August By Investing.com - Investing.com Canada
Candel Therapeutics Q2 Loss Widens - marketscreener.com
Earnings Flash (CADL) Candel Therapeutics Posts Q2 Net Loss $0.52 a Share, vs. FactSet Est of $0.21 Loss - marketscreener.com
Candel Therapeutics, Inc. Q2 2026: Net income $(38.9M), EPS $(0.52) — 10-Q Summary - TradingView
Candel Therapeutics (NASDAQ: CADL) widens H1 2026 loss while boosting cash above $200M - Stock Titan
Candel Therapeutics reports Q2 2026 net loss $38.9M, cash $201.6M; plans BLA submission Q4 2026 - TradingView
Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - The Manila Times
Candel's Prostate Therapy Candidate Shows 39% Disease-Free Survival Improvement - Stock Titan
CADL Stock Edges Up After Hours On Strong Extended Prostate Cancer Data - Stocktwits
Candel Therapeutics at canaccord growth conference: prostate cancer push By Investing.com - Investing.com Canada
Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up - MarketBeat
Candel Therapeutics at canaccord growth conference: prostate cancer push - Investing.com
Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today - Stocktwits
Candel Therapeutics (CADL) Holds Near $10.56 as Biotech Stock Tests Key ResistanceChaikin Flow - dars.gov.et
Janus Henderson Group PLC Makes New Investment in Candel Therapeutics, Inc. $CADL - MarketBeat
Candel Therapeutics (CADL) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Candel Therapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Candel Therapeutics Inc (CADL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Wall Street Zen Upgrades Candel Therapeutics (NASDAQ:CADL) to "Hold" - MarketBeat
Candel Therapeutics Inc (CADL) Stock News Today - TradingKey
Candel Therapeutics: Getting Closer, And Building Out More Paths (NASDAQ:CADL) - Seeking Alpha
(CADL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Candel Therapeutics (CADL) Expected to Announce Earnings on Thursday - MarketBeat
Candel Therapeutics Insider Ups Holding By 14% During Year - Moomoo
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Candel Therapeutics to present prostate cancer data at ASTRO - Investing.com
Candel Therapeutics to present prostate cancer data at ASTRO By Investing.com - Investing.com Australia
Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026 - GlobeNewswire
Three New Employees Receive Candel Options at $10.01 - Stock Titan
H.C. Wainwright reiterates Candel Therapeutics stock rating at buy By Investing.com - Investing.com Nigeria
Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston - GlobeNewswire
1.80%
1.77%
大文字化:
|
ボリューム (24 時間):